A look back at a most successful therapeutic trial for Amyloidosis !
We are pleased to report that the trial is very promising and paves the way for a new therapy.
The results were announced at the European Heart Failure Congress in Prague this weekend.
This first trial paves the way for the possibility of removing amyloid deposits.
To summarize the trial, the anti-transthyretin amyloidosis deposit antibody reactivates your immune system which will clean up the amyloidosis deposits throughout the body.
Imaging examinations (scintigraphy and MRI, according to those performed in the centers) of the heart are in favor of a clear decrease of intracardiac deposits as well as decreases of the NTproBNP biomarker.
It will of course have to be confirmed in a larger trial currently under construction.
Find it here